Kumar Sanjiv
Overview
Explore the profile of Kumar Sanjiv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valerie N, Sanjiv K, Mortusewicz O, Zhang S, Alam S, Pires M, et al.
Nat Commun
. 2024 Dec;
15(1):10347.
PMID: 39643609
Cellular target engagement technologies enable quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. Here, we present cellular target engagement by accumulation of mutant as...
2.
Shen J, Guillen Mancina E, Chen S, Manolakou T, Gad H, Berglund U, et al.
Oncogenesis
. 2024 May;
13(1):17.
PMID: 38796460
The mitotic MTH1 inhibitor TH1579 is a dual inhibitor that inhibits mitosis and incorporation of oxidative DNA damage and leads to cancer-specific cell death. The response to immune checkpoint inhibitor...
3.
Pidugu V, Tharappel A, Kumari S, Sanjiv K
Front Endocrinol (Lausanne)
. 2023 Oct;
14:1292619.
PMID: 37818095
No abstract available.
4.
Shivatare S, Sanjiv K, Kikkeri R, Adamo R
Front Immunol
. 2022 Aug;
13:941474.
PMID: 35990665
No abstract available.
5.
Michel M, Benitez-Buelga C, Calvo P, Hanna B, Mortusewicz O, Masuyer G, et al.
Science
. 2022 Jun;
376(6600):1471-1476.
PMID: 35737787
Oxidative DNA damage is recognized by 8-oxoguanine (8-oxoG) DNA glycosylase 1 (OGG1), which excises 8-oxoG, leaving a substrate for apurinic endonuclease 1 (APE1) and initiating repair. Here, we describe a...
6.
Centio A, Estruch M, Reckzeh K, Sanjiv K, Vittori C, Engelhard S, et al.
Mol Cancer Ther
. 2022 Mar;
21(5):703-714.
PMID: 35247918
Currently, the majority of patients with acute myeloid leukemia (AML) still die of their disease due to primary resistance or relapse toward conventional reactive oxygen species (ROS)- and DNA damage-inducing...
7.
Bonagas N, Gustafsson N, Henriksson M, Marttila P, Gustafsson R, Wiita E, et al.
Nat Cancer
. 2022 Mar;
3(2):156-172.
PMID: 35228749
The folate metabolism enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase/cyclohydrolase) is consistently overexpressed in cancer but its roles are not fully characterized, and current candidate inhibitors have limited potency for clinical development. In...
8.
Sanjiv K, Calderon-Montano J, Pham T, Erkers T, Tsuber V, Almlof I, et al.
Cancer Res
. 2021 Oct;
81(22):5733-5744.
PMID: 34593524
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential...
9.
Karsten S, Fiskesund R, Zhang X, Marttila P, Sanjiv K, Pham T, et al.
Cell Death Differ
. 2021 Aug;
29(1):246-261.
PMID: 34453118
T cell-driven diseases account for considerable morbidity and disability globally and there is an urgent need for new targeted therapies. Both cancer cells and activated T cells have an altered...
10.
Zhao Z, Gad H, Benitez-Buelga C, Sanjiv K, Xiangwei H, Kang H, et al.
Cancer Res
. 2021 May;
81(15):4079-4093.
PMID: 34045188
Patients with hepatocellular carcinoma (HCC) suffer from few treatment options and poor survival rates. Here we report that endonuclease VIII-like protein 3 (NEIL3) is overexpressed in HCC and correlates with...